Eurofins Scientific saw the highest growth of 3.99% in patent filings in June and 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Eurofins Scientific‘s patent filings and grants. Buy the databook here.
Eurofins Scientific has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 40% filings and 50% grants. The United States(US), European Patent Office(EPO), World Intellectual Property Organization(WIPO), and Spain(ES) patent Office are among the top ten patent offices where Eurofins Scientific is filings its patents. Among the top granted patent authorities, Eurofins Scientific has 50% of its grants in United States(US) and 50% in Spain(ES).
Immatics and Roche could be the strongest competitors for Eurofins Scientific
Patents related to genomics and rare diseases lead Eurofins Scientific's portfolio
Eurofins Scientific has the highest number of patents in genomics followed by, rare diseases and cell & gene therapy. For genomics, nearly 25% of patents were filed and no patents were granted in Q2 2024.
Healthcare it related patents lead Eurofins Scientific portfolio
Eurofins Scientific has highest number of patents in healthcare it.
For comprehensive analysis of Eurofins Scientific's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.